About ARA-290 - Nerve & Tissue Repair Peptide

Ara-290 (Cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 which is distinct from the classical erythropoietin receptor. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin.

WHAT THE RESEARCH SHOWS:

* Activates the Innate Repair Receptor (IRR): Unlike whole EPO, ARA-290 specifically targets the Innate Repair Receptor (EPOR/CD131 heterodimer). This means it delivers the powerful tissue-protective and anti-inflammatory properties of EPO without the risks of thickening the blood or causing blood clots.
* Small Fiber Neuropathy & Nerve Regeneration: This is where ARA-290 has the strongest clinical data. In Phase 2 human trials (particularly in patients with sarcoidosis and type 2 diabetes), ARA-290 was shown to stimulate the regrowth of small nerve fibers—confirmed via corneal confocal microscopy and skin biopsies—while significantly reducing chronic neuropathic pain and burning sensations.
* Potent Anti-Inflammatory Action: Research shows it rapidly downregulates pro-inflammatory cytokines like TNF-α and IL-6, helping switch macrophages from a pro-inflammatory (M1) state to a healing/repair (M2) state.
* Ischemia & Organ Protection: Preclinical animal studies show strong protective effects against ischemia-reperfusion injury in kidneys, heart tissue, and retinas by preventing cellular apoptosis (cell death). The Bottom Line: ARA-290 is one of the most promising peptides specifically studied for nerve repair and neuropathic pain. For broader tissue, tendon, or muscle recovery, the GLOW combo (BPC-157 + TB-500 + GHK-Cu) is generally the gold standard for full-spectrum healing, but ARA-290 has uniquely strong clinical backing when nerve-specific damage is the primary issue.

STUDIES

Culver et al., 2017 – Phase 2b dose-ranging RCT (Investigative Ophthalmology & Visual Science). 64 patients received 1, 4 or 8 mg/day or placebo for 28 days. Small nerve fibre abundance rose significantly in both cornea and skin, which the authors described as consistent with a disease-modifying effect. Only the 4 mg dose reached significance: corneal nerve fibre area rose by 697 µm²/mm² more than placebo. Manchester abstract - LINK
Heij et al., 2012 – pilot RCT (Molecular Medicine). 22 patients received 2 mg intravenously three times a week, or placebo, for 4 weeks. The ARA-290 group improved significantly more than placebo on a small fibre neuropathy symptom score. It also improved from baseline on the pain and physical-functioning measures of a quality-of-life questionnaire. The authors concluded it appeared safe and reduced neuropathic symptoms. Leiden PDF - LINK

Lyophilised powder